Mechanism

We propose that microbial SCFAs—acetate, propionate, butyrate—released in the colon activate enteroendocrine cells and vagal afferents. These afferents signal to the nucleus tractus solitarius, increasing central cholinergic output via the dorsal motor nucleus of the vagus. Enhanced vagal cholinergic effervescence releases acetylcholine at the neuromuscular junction and within muscle interstitium, activating muscarinic receptors that stimulate phospholipase C‑IP3 pathways, causing modest, transient calcium releases from the sarcoplasmic reticulum. These calcium transients are insufficient to fully activate calcineurin but are enough to keep the phosphatase in a low‑activity state by promoting phosphorylation of its regulatory subunits via CaMKII. Consequently, NFAT4 remains phosphorylated, cytosolic, and unable to drive transcription of atrogenes such as atrogin‑1 and MuRF1. When SCFA signaling drops—due to dysbiosis, antibiotics, or vagotomy—cholinergic tone falls, calcium spikes become larger and more sustained, calcineurin activity rises, NFAT4 dephosphorylates, translocates to the nucleus, and the atrophy program initiates.

Testable Predictions

1. Germ‑free mice will show reduced vagal afferent firing (measured by extracellular recordings) and lower baseline acetylcholine levels in muscle interstitial fluid compared with conventionally raised littermates.
2. Restoring SCFA levels by oral gavage of a mixed SCFA cocktail will increase vagal afferent activity and muscle acetylcholine, decrease calcineurin phosphatase activity, and keep NFAT4 cytosolic despite an atrophy stimulus (e.g., glucocorticoid treatment).
3. Subdiaphragmatic vagotomy will abolish the protective effect of SCFA supplementation on NFAT4 localization, leading to nuclear NFAT4 accumulation and increased MuRF1 mRNA even when SCFAs are present.
4. Pharmacological blockade of muscarinic receptors in muscle (with atropine) will mimic vagotomy, preventing SCFA‑mediated inhibition of calcineurin and resulting in NFAT4 nuclear shift.

Experimental Approach

• Use male C57BL/6 mice, 8 weeks old, divided into: (a) conventional, (b) germ‑free, (c) germ‑free + SCFA cocktail, (d) conventional + vagotomy, (e) conventional + vagotomy + SCFA, (f) conventional + atropine.
• Treat subsets with dexamethasone (10 mg/kg, i.p.) for 24 h to induce atrophy.
• Measure: vagal afferent firing (in vivo electrophysiology), muscle interstitial ACh (microdialysis), calcineurin activity (phosphatase assay), NFAT4 localization (immunofluorescence and subcellular fractionation), atrogene mRNA (qPCR), muscle cross‑sectional area (histology).
• Statistical analysis: two‑way ANOVA with factors SCFA and vagal integrity, post‑hoc Tukey.

Falsifiability

If SCFA supplementation fails to increase vagal afferent firing or muscle ACh, or if NFAT4 still translocates to the nucleus despite intact vagal cholinergic signaling, the hypothesis is refuted. Likewise, if vagotomy does not exacerbate NFAT4 nuclear localization under SCFA repletion, the proposed afferent pathway is not necessary.